Exploring the Practice-changing Implications of the ADtouch Study With Dr. Shawn G. Kwatra

Lebrikizumab (Ebglyss, Lilly/Almirall) improves hand and foot lesions, itch, and pain in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis (AD), according to Phase 3b data from the ADtouch study presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.

ADtouch is a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of lebrikizumab 250mg dosed every two weeks (Q2W) in patients with moderate-to-severe atopic hand and foot AD for 16 weeks. The trial assessed physician- and patient-reported outcomes across skin clearance, itch, pain, patient satisfaction with hand clearance, and quality of life. At baseline, patients were living with severe itch of the hands and feet, moderate pain, and substantial impairment in quality of life, despite limited overall skin involvement.

Shawn G. Kwatra, MD, Joseph W. Burnett Endowed Professor and Chair in Dermatology, Chief of Service in Dermatology at the University of Maryland School of Medicine and University of Maryland Medical Center in Baltimore, MD, talked to TDD about the findings and their implications for AD patients and clinicians.

TDD: Why does AD on the hands and feet pose such a significant burden for patients, and why is it so hard to treat?

Shawn G. Kwatra, MD: “Hands and feet are particularly difficult to treat as they are under constant mechanical and environmental stress because of handwashing, using sanitizers, or walking, and this can make it harder for the skin barrier to recover. The burden is greater than body surface area (BSA) alone would suggest. Topicals can be difficult in these patients as they are constantly using and washing the affected areas.”

TDD: What does the study tell us?

Dr. Kwatra: “There were significant and rapid improvements in skin clearance, as early as one month, including more than half (53%) of patients achieving Clear or Almost Clear skin on their hands and feet by Week 16. Lebrikizumab also produces significant itch and pain relief, with significant itch improvements as early as two weeks. These are incredible results, and pain is also an important feature of hand and foot eczema. Significantly more patients treated with lebrikizumab were satisfied or very satisfied with how much the skin on their hands had cleared than those on placebo, as measured by the validated Atopic Hand Dermatitis Clearance Satisfaction (AHDCS) scale. The safety profile is consistent with previous lebrikizumab studies, with no new safety finding seen.

“ADtouch is a particularly robust study that shows us why BSA alone can be slightly misleading when deciding who may benefit from systemic AD therapy. The study supports a broader way of deciding on systemic therapy. For special sites, a low BSA doesn’t mean mild disease.”

TDD: How should these findings guide practice?

Dr. Kwatra: “We can look beyond BSA in these AD patients with high functional burden.

“This is increasingly the direction that we are moving in clinically. Psoriasis has truly led the way. Historically, systemic treatment of AD was heavily anchored to BSA. ADtouch is consistent with where things are moving and adds randomized evidence regarding this specific AD phenotype. It will move the needle more and will shift the paradigm from how much skin is involved to how much the disease is affecting the AD patient.”

Key Efficacy Results in ADtouch
EBGLYSS   Placebo  
Significant and rapid
improvements in skin
clearance
Clear or Almost Clear hands and feet
(HF-IGA 0/1 with ≥2-point
improvement) at Week 16 (primary
endpoint)*
53% 27%
HF-IGA 0/1 with ≥2-point
improvement at Week 4*
17% 6%
Significant and rapid
improvements in hand and
foot itch
HF-Peak Pruritus NRS ≥4-point
improvement at Week 16* †
57% 19%
HF-Peak Pruritus NRS ≥4-point
improvement at Week 4* †
27% 8%
HF-Peak Pruritus NRS ≥4-point
improvement at Week 2* †
16% 1%
Significant improvements in
hand and foot pain
HF-Peak Pain NRS ≥4-point
improvement at Week 16* ‡
59% 19%
HF-Peak Pain NRS ≥ 4-point
improvement at Week 2‡
24% 3%
HF-Peak Pain NRS ≥4-point
improvement at Week 1‡
8% 0%
Significant improvements in
patient-reported outcomes
Satisfied or very satisfied with hand
dermatitis clearance at Week 16* §
77% 40%
Mean improvement in impact of
hand disease on quality of life||
57% 28%
Less need for topical and
systemic rescue medication
Patients requiring rescue medication
through Week 16
6% 18%

* Statistically significant under multiplicity control
† Among patients with HF-Peak Pruritus Numeric Rating Scale (NRS) ≥4 at baseline, rating itch from 0-10 with 10 being worst imaginable itch within the past 24 hours
‡ Among patients with HF-Peak Pain NRS ≥4 at baseline, rating pain from 0-10 with 10 being worst imaginable pain within the past 24 hours
§ Among patients dissatisfied with their hand dermatitis clearance at baseline, as measured by the novel Atopic Hand Dermatitis Clearance Satisfaction (AHDCS) patient-reported scale.
|| Measured by the Quality of Life in Hand Eczema Questionnaire (QoLHEQ)